Clinical Trial Update: A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase Ib/II study evaluating BYL719 (alpelisib) in combination with AMG 479 (motesanib) in adults with PIK3CA-mutated or PIK3CA-amplified advanced solid tumor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pik3ca-amplified Advanced Solid Tumors
• Pik3ca-mutated Advanced Solid Tumors

Drugs mentioned

• AMG 479
• BYL719 (alpelisib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: PIK3CA Mutated Advanced Solid Tumors, PIK3CA Amplified Advanced Solid Tumors | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2018-06-28